FAKTOR-OPTIONSSCHEIN - MODERNA | Delayed Deutsche Boerse AG 05:17:14 2024-06-06 am EDT | ||
| 10.28 EUR | -1.53% |
|
| Current month | -17.60% | ||
| 1 month | -45.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 10.28 | -1.53% |
| 24-06-05 | 10.44 | -14.50% |
| 24-06-04 | 12.21 | +4.81% |
| 24-06-03 | 11.65 | -8.05% |
| 24-05-31 | 12.67 | +11.93% |
Delayed Quote Deutsche Boerse AG
Last update June 06, 2024 at 05:17 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ6JC9 |
| ISIN | DE000SQ6JC95 |
| Date issued | 2022-12-20 |
| Strike | 192.8 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 20.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 99.62 € |
|---|---|
| Lowest since issue | 9.29 € |
| Spread | 0.08 € |
| Spread % | 0.77% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
154.8
USD
Average target price
142.8
USD
Spread / Average Target
-7.77%
- Stock Market
- Certificates
- Certificat
